Nivolumab + Ipilimumab Front Line bevacizumab atezolizumab

Nivolumab + Ipilimumab Front Line bevacizumab atezolizumab

User Photo
moasc

2 years
92 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical Oncologist, shares thoughts on Nivolumab + Ipilimumab at the 2018 Oncology Summit in Huntington Beach, CA Go to: http://www.moasc.org for more information
Up Next Autoplay